Skip to content
Exjade(deferasirox)
Exjade, Jadenu (deferasirox) is a small molecule pharmaceutical. Deferasirox was first approved as Exjade on 2005-11-02. It is used to treat iron overload in the USA. It has been approved in Europe to treat beta-thalassemia and iron overload.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Exjade, Jadenu (generic drugs available since 2016-01-26)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deferasirox
Tradename
Company
Number
Date
Products
EXJADENovartisN-021882 RX2005-11-02
3 products, RLD, RS
JADENU SPRINKLENovartisN-207968 RX2017-05-18
3 products, RLD, RS
JADENUNovartisN-206910 RX2015-03-30
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
deferasiroxANDA2023-02-28
exjadeNew Drug Application2020-12-11
jadenuNew Drug Application2020-07-23
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
iron overload—D019190—
Agency Specific
FDA
EMA
Expiration
Code
DEFERASIROX, EXJADE, NOVARTIS
2023-07-23M-263
DEFERASIROX, JADENU, NOVARTIS PHARMS CORP
2023-07-23M-263
DEFERASIROX, JADENU SPRINKLE, NOVARTIS
2023-07-23M-263
Patent Expiration
Patent
Expires
Flag
FDA Information
Deferasirox, Jadenu, Novartis Pharms Corp
92832092034-11-21DS, DP
ATC Codes
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AC: Iron chelating agents
— V03AC03: Deferasirox
HCPCS
No data
Clinical
Clinical Trials
93 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Iron overloadD01919011236424
Myelodysplastic syndromesD009190D46—1217121
Beta-thalassemiaD017086Orphanet_848D56.1—735216
ThalassemiaD013789EFO_1001996D563523213
HemosiderosisD006486—542111
Sickle cell anemiaD000755EFO_0000697D57—531—8
AnemiaD000740EFO_0004272D64.9—4—127
Diamond-blackfan anemiaD029503D61.01—111—3
Aplastic anemiaD000741HP_0001915D61.9—1—1—2
HemoglobinopathiesD006453D58.2———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Primary myelofibrosisD055728D47.4—21——3
Porphyria cutanea tardaD017119E80.1—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.013———4
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.012———3
Non-hodgkin lymphomaD008228C85.9—2———2
Multiple myelomaD009101C90.0—2———2
B-cell chronic lymphocytic leukemiaD015451C91.1—2———2
Hodgkin diseaseD006689C81—2———2
B-cell lymphoma marginal zoneD018442C88.4—2———2
Follicular lymphomaD008224C82—2———2
Mantle-cell lymphomaD020522C83.1—2———2
Large b-cell lymphoma diffuseD016403C83.3—2———2
Show 34 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
Hepatic insufficiencyD0485501————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemiaD007951C92————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDEFERASIROX
INNdeferasirox
Description
Deferasirox, sold under the brand name Exjade & Asunra (in injectable form) & Oleptiss (Tablet formulation) both by Novartis among others, is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the United States for this purpose.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1
Identifiers
PDB—
CAS-ID201530-41-8
RxCUI614373
ChEMBL IDCHEMBL550348
ChEBI ID49005
PubChem CID5493381
DrugBankDB01609
UNII IDV8G4MOF2V9 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Exjade - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,187 documents
View more details
Safety
Black-box Warning
Black-box warning for: Deferasirox, Exjade, Jadenu
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,594 adverse events reported
View more details